European Heart Journal — Cardiovascular Pharmacotherapy最新文献

{"title":"Dronedarone vs. placebo in patients with atrial fibrillation or atrial flutter across a range of renal function: a post hoc analysis of the ATHENA trial.","authors":"Mate Vamos,&nbsp;Jonas Oldgren,&nbsp;Gi-Byoung Nam,&nbsp;Gregory Y H Lip,&nbsp;Hugh Calkins,&nbsp;Jun Zhu,&nbsp;Kwo-Chang Ueng,&nbsp;Ulf Ludwigs,&nbsp;Mattias Wieloch,&nbsp;John Stewart,&nbsp;Stefan H Hohnloser","doi":"10.1093/ehjcvp/pvab090","DOIUrl":"https://doi.org/10.1093/ehjcvp/pvab090","url":null,"abstract":"<p><strong>Aims: </strong>Use of antiarrhythmic drugs (AADs) in patients with chronic kidney disease (CKD) is challenging owing to issues with renal clearance, drug accumulation, and increased proarrhythmic risks. Because CKD is a common comorbidity in patients with atrial fibrillation/atrial flutter (AF/AFL), it is important to establish the efficacy and safety of AAD treatment in patients with CKD.</p><p><strong>Methods and results: </strong>Dronedarone efficacy and safety in individuals with AF/AFL and varying renal functionality [estimated glomerular filtration rate (eGFR): ≥60, ≥45 and <60, and <45 mL/min] was investigated in a post hoc analysis of ATHENA (NCT00174785), a randomized, double-blind trial of dronedarone vs. placebo in patients with paroxysmal or persistent AF/AFL plus additional cardiovascular (CV) risk factors. Log-rank testing and Cox regression were used to compare the incidence of endpoints between treatments. Overall, 4588 participants were enrolled from the trial. There was no interaction between treatment group and baseline eGFR assessed as a continuous variable (P = 0.743) for the first CV hospitalization or death from any cause (primary outcome). This outcome was lower with dronedarone vs. placebo across a wide range of renal function. First CV hospitalization and first AF/AFL recurrence were both lower in the two least renally impaired subgroups with dronedarone vs. placebo. Treatment emergent adverse events leading to treatment discontinuation were more frequent with dronedarone vs. placebo and occurred more often in patients with severe renal impairment.</p><p><strong>Conclusion: </strong>Dronedarone is an effective AAD in patients with AF/AFL and CV risk factors across a wide range of renal function.</p>","PeriodicalId":11995,"journal":{"name":"European Heart Journal — Cardiovascular Pharmacotherapy","volume":" ","pages":"363-371"},"PeriodicalIF":7.1,"publicationDate":"2022-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f9/54/pvab090.PMC9175188.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39642332","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of digoxin vs. beta blocker in atrial fibrillation: report from ESC-EHRA EORP AF Long-Term General Registry.","authors":"Wern Yew Ding,&nbsp;Giuseppe Boriani,&nbsp;Francisco Marin,&nbsp;Carina Blomström-Lundqvist,&nbsp;Tatjana S Potpara,&nbsp;Laurent Fauchier,&nbsp;Gregory Y H Lip","doi":"10.1093/ehjcvp/pvab076","DOIUrl":"https://doi.org/10.1093/ehjcvp/pvab076","url":null,"abstract":"<p><strong>Aims: </strong>The safety of digoxin therapy in atrial fibrillation (AF) remains ill-defined. We aimed to evaluate the effects of digoxin over beta-blocker therapy in AF.</p><p><strong>Methods and results: </strong>Patients with AF who were treated with either digoxin or a beta blocker from the ESC-EHRA EORP AF (European Society of Cardiology-European Heart Rhythm Association EURObservational Research Programme Atrial Fibrillation) General Long-Term Registry were included. Outcomes of interest were all-cause mortality, cardiovascular (CV) mortality, non-CV mortality, quality of life, and number of patients with unplanned hospitalizations. Of 6377 patients, 549 (8.6%) were treated with digoxin. Over 24 months, there were 550 (8.6%) all-cause mortality events and 1304 (23.6%) patients with unplanned emergency hospitalizations. Compared to beta blocker, digoxin therapy was associated with increased all-cause mortality [hazard ratio (HR) 1.90 (95% confidence interval, CI, 1.48-2.44)], CV mortality [HR 2.18 (95% CI 1.47-3.21)], and non-CV mortality [HR 1.68 (95% CI 1.02-2.75)] with reduced quality of life [health utility score 0.555 (±0.406) vs. 0.705 (±0.346), P < 0.001] but no differences in emergency hospitalizations [HR 1.00 (95% CI 0.56-1.80)] or AF-related hospitalizations [HR 0.95 (95% CI 0.60-1.52)]. On multivariable analysis, there were no differences in any of the outcomes between both groups, after accounting for potential confounders. Similar results were obtained in the subgroups of patients with permanent AF and coexisting heart failure. There were no differences in outcomes between AF patients receiving digoxin with and without chronic kidney disease.</p><p><strong>Conclusion: </strong>Poor outcomes related to the use of digoxin over beta-blocker therapy in terms of excess mortality and reduced quality of life are associated with the presence of other risk factors rather than digoxin per se. The choice of digoxin or beta-blocker therapy had no influence on the incidence of unplanned hospitalizations.</p>","PeriodicalId":11995,"journal":{"name":"European Heart Journal — Cardiovascular Pharmacotherapy","volume":" ","pages":"372-382"},"PeriodicalIF":7.1,"publicationDate":"2022-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39530651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Discontinuation of direct oral anticoagulants among patients with atrial fibrillation according to gender and cohabitation status: a nationwide cohort study.","authors":"Casper Binding,&nbsp;Jonas Bjerring Olesen,&nbsp;Christina Ji-Young Lee,&nbsp;Gregory Y H Lip,&nbsp;Caroline Sindet-Pedersen,&nbsp;Gunnar Gislason,&nbsp;Anders Nissen Bonde","doi":"10.1093/ehjcvp/pvab065","DOIUrl":"https://doi.org/10.1093/ehjcvp/pvab065","url":null,"abstract":"<p><strong>Aims: </strong>The aim of this study was to evaluate the risk of discontinuing treatment with direct oral anticoagulants (DOACs) among patients with atrial fibrillation (AF) according to cohabitation status and gender.</p><p><strong>Methods and results: </strong>Using the Danish national registers, we identified 32 364 patients with AF aged 40-90 years undergoing treatment with DOACs. The study period was from 2013 to 2017, and patients were followed for 2 years, or until death, outcome, or emigration. The main outcome was discontinuation of DOAC treatment for at least 30 days. The absolute 2-year risk of DOAC discontinuation was highest among men living alone [35.7%, 95% confidence interval (CI): 37.3-34.1%]. Men living alone had a 4.6% (95% CI: 6.4-2.8%) higher absolute risk of discontinuation and a 12% [hazard ratio (HR): 1.12, 95% CI: 1.04-1.20] higher relative risk of discontinuation compared with men living with a partner. Female patients living alone likewise had a higher absolute risk of DOAC discontinuation (2.6%, 95% CI: 4.4-0.09%) compared with female patients living with a partner, yet no statistically significant difference in relative risk. In an analysis evaluating gender, we found male gender to be associated with a significantly higher relative risk of DOAC discontinuation (HR: 1.33, 95% CI: 1.26-1.40) compared with female gender (P-value for interaction with cohabitant status = 0.5996).</p><p><strong>Conclusion: </strong>In this nationwide population study, male gender and living alone were associated with a higher risk of DOAC discontinuation among patients with AF.</p>","PeriodicalId":11995,"journal":{"name":"European Heart Journal — Cardiovascular Pharmacotherapy","volume":" ","pages":"353-362"},"PeriodicalIF":7.1,"publicationDate":"2022-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39341928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comments on-The noradrenaline dosing in the new 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.","authors":"Geir Øystein Andersen","doi":"10.1093/ehjcvp/pvab086","DOIUrl":"https://doi.org/10.1093/ehjcvp/pvab086","url":null,"abstract":"","PeriodicalId":11995,"journal":{"name":"European Heart Journal — Cardiovascular Pharmacotherapy","volume":" ","pages":"E11"},"PeriodicalIF":7.1,"publicationDate":"2022-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39610544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Current evidence and future perspective for the management of left-sided prosthetic valve thrombosis.","authors":"Ahmet Güner,&nbsp;Macit Kalçık,&nbsp;Sabahattin Gündüz","doi":"10.1093/ehjcvp/pvac011","DOIUrl":"https://doi.org/10.1093/ehjcvp/pvac011","url":null,"abstract":"","PeriodicalId":11995,"journal":{"name":"European Heart Journal — Cardiovascular Pharmacotherapy","volume":" ","pages":"E20"},"PeriodicalIF":7.1,"publicationDate":"2022-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39610980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antithrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCI.","authors":"Francesco Costa,&nbsp;Marco Valgimigli,&nbsp;Philippe Gabriel Steg,&nbsp;Deepak L Bhatt,&nbsp;Stefan H Hohnloser,&nbsp;Jurrien M Ten Berg,&nbsp;Corinna Miede,&nbsp;Matias Nordaby,&nbsp;Gregory Y H Lip,&nbsp;Jonas Oldgren,&nbsp;Christopher P Cannon","doi":"10.1093/ehjcvp/pvaa135","DOIUrl":"https://doi.org/10.1093/ehjcvp/pvaa135","url":null,"abstract":"<p><strong>Aims: </strong>Patients with atrial fibrillation undergoing coronary intervention are at higher bleeding risk due to the concomitant need for oral anticoagulation and antiplatelet therapy. The RE-DUAL PCI trial demonstrated better safety with dual antithrombotic therapy (DAT: dabigatran 110 or 150 mg b.i.d., clopidogrel or ticagrelor) compared to triple antithrombotic therapy (TAT: warfarin, clopidogrel or ticagrelor, and aspirin). We explored the impact of baseline bleeding risk based on the PRECISE-DAPT score for decision-making regarding DAT vs. TAT.</p><p><strong>Methods and results: </strong>A score ≥25 points qualified high bleeding risk (HBR). Comparisons were made for the primary safety endpoint International Society of Thrombosis and Haemostasis major or clinically relevant non-major bleeding, and the composite efficacy endpoint of death, thrombo-embolic events, or unplanned revascularization, analysed by time-to-event analysis. PRECISE-DAPT was available in 2336/2725 patients, and 37.9% were HBR. Compared to TAT, DAT with dabigatran 110 mg reduced bleeding risk both in non-HBR [hazard ratio (HR) 0.42, 95% confidence interval (CI) 0.31-0.57] and HBR (HR 0.70, 95% CI 0.52-0.94), with a greater magnitude of benefit among non-HBR (Pint = 0.02). Dual antithrombotic therapy with dabigatran 150 mg vs. TAT reduced bleeding in non-HBR (HR 0.60, 95% CI 0.45-0.80), with a trend toward less benefit in HBR patients (HR 0.92, 95% CI 0.63-1.34; Pint = 0.08). The risk of ischaemic events was similar on DAT with dabigatran (both 110 and 150 mg) vs. TAT in non-HBR and HBR patients (Pint = 0.45 and Pint = 0.56, respectively).</p><p><strong>Conclusions: </strong>PRECISE-DAPT score appeared useful to identify AF patients undergoing PCI at further increased risk of bleeding complications and may help clinicians identifying the antithrombotic regimen intensity with the best benefit-risk ratio in an individual patient.</p>","PeriodicalId":11995,"journal":{"name":"European Heart Journal — Cardiovascular Pharmacotherapy","volume":" ","pages":"216-226"},"PeriodicalIF":7.1,"publicationDate":"2022-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1093/ehjcvp/pvaa135","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38658213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Updated meta-analysis of randomized controlled trials on the safety and efficacy of different prophylactic anticoagulation dosing regimens in non-critically ill hospitalized patients with COVID-19.","authors":"Luis Ortega-Paz,&nbsp;Mattia Galli,&nbsp;Dominick J Angiolillo","doi":"10.1093/ehjcvp/pvac010","DOIUrl":"https://doi.org/10.1093/ehjcvp/pvac010","url":null,"abstract":"We thank Prof. Čulić and colleagues for their interest in our meta-analysis on the safety and efficacy of different prophylactic anticoagulation dosing regimens in coronavirus disease 2019 (COVID-19) patients.1 Throughout the COVID-19 pandemic, the high rate of thromboembolic events among COVID-19 patients has been a topic of extensive and ongoing research.2,3 Several randomized controlled trials (RCTs) have tested different anticoagulation regimens for preventing thromboembolic events.1 However, the results of the RCTs have not been univocal, and the majority of these lack statistical power for individual hard endpoints such as death. For these reasons, we pooled the data on the safety and efficacy of prophylactic anticoagulation at escalated dose vs. standard dose in critically and non-critically ill hospitalized patients with COVID-19. This meta-analysis did not find any mortality benefit of an escalated dose over the standard dose of prophylactic anticoagulation. Moreover, there was a reduction of venous thromboembolism (VTE) counterbalanced by increased major bleeding in patients treated with escalated-dose prophylactic anticoagulation compared with those treated with a standard dose.1 As the evidence has constantly been evolving after the publication of our meta-analysis (14 September 2021), further RCTs have become available in the setting of non-critically ill hospitalized patients.4–6 The HEP-COVID trial, published on 7 October 2021, is the most relevant.4 We agree with the authors that in non-critically ill hospitalized patients, the data reported by the HEP-COVID and the ATTACC, ACTIV-4a, and REMAP-CAP trials may suggest improved outcomes with an escalated dose of prophylactic anticoagulation compared with the standard dose.4,7 Briefly, HEP-COVID showed a reduction of the primary endpoint (composite","PeriodicalId":11995,"journal":{"name":"European Heart Journal — Cardiovascular Pharmacotherapy","volume":" ","pages":"E15-E17"},"PeriodicalIF":7.1,"publicationDate":"2022-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9383405/pdf/pvac010.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39880600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rationale and design of the pragmatic clinical trial tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT).","authors":"Xavier Rossello,&nbsp;Sergio Raposeiras-Roubin,&nbsp;Roberto Latini,&nbsp;Alberto Dominguez-Rodriguez,&nbsp;José A Barrabés,&nbsp;Pedro L Sánchez,&nbsp;Manuel Anguita,&nbsp;Felipe Fernández-Vázquez,&nbsp;Domingo Pascual-Figal,&nbsp;José M De la Torre Hernandez,&nbsp;Stefano Ferraro,&nbsp;Alfredo Vetrano,&nbsp;José A Pérez-Rivera,&nbsp;Oscar Prada-Delgado,&nbsp;Noemí Escalera,&nbsp;Lidia Staszewsky,&nbsp;Gonzalo Pizarro,&nbsp;Jaume Agüero,&nbsp;Stuart Pocock,&nbsp;Filippo Ottani,&nbsp;Valentín Fuster,&nbsp;Borja Ibáñez","doi":"10.1093/ehjcvp/pvab060","DOIUrl":"https://doi.org/10.1093/ehjcvp/pvab060","url":null,"abstract":"<p><strong>Aims: </strong>There is a lack of evidence regarding the benefits of β-blocker treatment after invasively managed acute myocardial infarction (MI) without reduced left ventricular ejection fraction (LVEF).</p><p><strong>Methods and results: </strong>The tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT) trial is a pragmatic, controlled, prospective, randomized, open-label blinded endpoint (PROBE design) clinical trial testing the benefits of β-blocker maintenance therapy in patients discharged after MI with or without ST-segment elevation. Patients eligible for participation are those managed invasively during index hospitalization (coronary angiography), with LVEF >40%, and no history of heart failure (HF). At discharge, patients will be randomized 1:1 to β-blocker therapy (agent and dose according to treating physician) or no β-blocker therapy. The primary endpoint is a composite of all-cause death, non-fatal reinfarction, or HF hospitalization over a median follow-up period of 2.75 years (minimum 2 years, maximum 3 years). Key secondary endpoints include the incidence of the individual components of the primary composite endpoint, the incidence of cardiac death, and incidence of malignant ventricular arrhythmias or resuscitated cardiac arrest. The primary endpoint will be analysed according to the intention-to-treat principle.</p><p><strong>Conclusion: </strong>The REBOOT trial will provide robust evidence to guide the prescription of β-blockers to patients discharged after MI without reduced LVEF.</p>","PeriodicalId":11995,"journal":{"name":"European Heart Journal — Cardiovascular Pharmacotherapy","volume":" ","pages":"291-301"},"PeriodicalIF":7.1,"publicationDate":"2022-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39277950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to-Current evidence and future perspective for the management of left sided prosthetic valve thrombosis.","authors":"Parham Sadeghipour,&nbsp;Sedigheh Saedi,&nbsp;Zahra Khajali,&nbsp;Raffaele De Caterina","doi":"10.1093/ehjcvp/pvac013","DOIUrl":"https://doi.org/10.1093/ehjcvp/pvac013","url":null,"abstract":"","PeriodicalId":11995,"journal":{"name":"European Heart Journal — Cardiovascular Pharmacotherapy","volume":" ","pages":"E21-E22"},"PeriodicalIF":7.1,"publicationDate":"2022-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39608208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recombinant human lecithin-cholesterol acyltransferase in patients with atherosclerosis: phase 2a primary results and phase 2b design.","authors":"Marc P Bonaca,&nbsp;Richard T George,&nbsp;David A Morrow,&nbsp;Brian A Bergmark,&nbsp;Jeong-Gun Park,&nbsp;Liron Abuhatzira,&nbsp;Andrea L Vavere,&nbsp;Sotirios K Karathanasis,&nbsp;ChaoYu Jin,&nbsp;Dewei She,&nbsp;Boaz Hirshberg,&nbsp;Judy Hsia,&nbsp;Marc S Sabatine","doi":"10.1093/ehjcvp/pvab001","DOIUrl":"https://doi.org/10.1093/ehjcvp/pvab001","url":null,"abstract":"<p><strong>Aims: </strong>Reverse cholesterol transport (RCT) removes cholesterol and stabilizes vulnerable plaques. In addition, high-density lipoprotein (HDL) may be cardioprotective in acute myocardial infarction (MI). Lecithin-cholesterol acyltransferase (LCAT) may enhance RCT. The objective of this study was to investigate the pharmacokinetics, pharmacodynamics, and safety of multiple ascending doses of recombinant human LCAT (MEDI6012) to inform a Phase 2b programme.</p><p><strong>Methods and results: </strong>This was a randomized, blinded, placebo-controlled, dose-escalation Phase 2a study of MEDI6012. Patients were randomized into one of four cohorts (40, 120, 300 mg IV weekly ×3 doses, or 300 mg IV-push, 150 mg at 48 h and 100 mg at 7 days). All cohorts were planned to randomize 6:2 (MEDI6012 vs. placebo). The primary endpoints were baseline-adjusted area under the curve (AUC) from 0 to 96 h post dose 3 (AUC 0-96 h) for HDL-C, HDL cholesteryl ester (HDL-CE), and total cholesteryl ester (CE). The primary safety endpoints were treatment-emergent adverse events. A total of 32 patients were randomized. MEDI6012 significantly increased AUC 0-96 h for HDL-C, HDL-CE and CE in a graded fashion with increasing doses. Relative to placebo, MEDI6012 increased HDL-C at Day 19 by 66% (95% CI 33-99, P = 0.014) with 120 mg and 144% (95% CI 108-181, P < 0.001) with 300 mg. An IV-push increased HDL-C by 40.8% at 30 min. Overall adverse events were similar between groups with no severe, life-threatening/fatal adverse events, or neutralizing antibodies.</p><p><strong>Conclusions: </strong>Multiple ascending doses of MEDI6012 were safe and well tolerated and significantly increased HDL-C, HDL-CE and CE in a dose-related manner. These data support the ongoing Phase 2b programme investigating MEDI6012 in ST-elevation MI.</p>","PeriodicalId":11995,"journal":{"name":"European Heart Journal — Cardiovascular Pharmacotherapy","volume":" ","pages":"243-252"},"PeriodicalIF":7.1,"publicationDate":"2022-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1093/ehjcvp/pvab001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38858312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}